4-Aminopyridine
Phase 1
4-Aminopyridine is one of 10 therapeutic programs targeting Paralysis. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
10 competitors in Paralysis
#DrugCompanyPhaseTrials
1Robinul
Jazz PharmaceuticalsApproved
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Relistor
SSalix
Approved
Movantik
AAveritas Pharma, Inc.
Approved
Naropin
FFresenius Kabi USA, LLC
Approved
GM-CSF
YY-mAbs Therapeutics
Phase 3
Buspar
Bristol-Myers SquibbPhase 1
Bayer Aspirin
BayerPreclinical
Marcaine
IInnocoll
Preclinical
4-Aminopyridine
MMilton S. Hershey Medical Center
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for 4-Aminopyridine. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- MMilton S. Hershey Medical Center